• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna to Present at Upcoming Conferences in June 2022

By: Moderna, Inc. via AccessWire
June 01, 2022 at 07:57 AM EDT

CAMBRIDGE, MA / ACCESSWIRE / June 1, 2022 / Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences:

  • 2022 Jefferies Healthcare Conference on Wednesday, June 8th at 3:00 p.m. ET
  • 43rd Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 14th at 12:20 p.m. ET

A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both ground-breaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: ModernaTX, Inc.



View source version on accesswire.com:
https://www.accesswire.com/703434/Moderna-to-Present-at-Upcoming-Conferences-in-June-2022

More News

View More
3 Stocks Flying Under the S&P 500 Radar
July 25, 2025
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
Tickers AAPL AEVA AMD GOOGL
Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing
July 25, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers AWEVF QCOM
3 Cloud Build-Out Stocks Behind the AI Infrastructure Boom
July 25, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers AMZN ANET META MSFT
ServiceNow: The 2nd Wave of AI Spending Is Here
July 25, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers NOW
Tractor Supply Revs Up on Forecast Hike and Bullish Signals
July 25, 2025
Via MarketBeat
Tickers TSCO
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap